Sonoma Pharmaceuticals, Inc. (SNOA) stock
SNOANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3081% below fair value
$0.88−0.21 (-19.25%)
Close on Nov 16, 2026Market cap $4.21MP/E –Yield –
Sonoma Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Sonoma Pharmaceuticals's profit margin for the twelve months ending Jun 30, 2026 was -10.3%. For fiscal 2026 it was -16.3%, against -24.2% the year before. The highest annual figure on record is 72.3% in fiscal 2017.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -16.3% | +7.9 |
| FY2025 | Mar 31, 2025 | -24.2% | +13.8 |
| FY2024 | Mar 31, 2024 | -38.0% | +0.8 |
| FY2023 | Mar 31, 2023 | -38.8% | +1.5 |
| FY2022 | Mar 31, 2022 | -40.3% | −19.1 |
| FY2021 | Mar 31, 2021 | -21.2% | −2.8 |
| FY2020 | Mar 31, 2020 | -18.5% | +43.7 |
| FY2019 | Mar 31, 2019 | -62.2% | +23.8 |
| FY2018 | Mar 31, 2018 | -86.0% | −158.3 |
| FY2017 | Mar 31, 2017 | 72.3% | +180.8 |
| FY2016 | Mar 31, 2016 | -108.5% | −49.3 |
| FY2015 | Mar 31, 2015 | -59.2% | −86.5 |
| FY2014 | Mar 31, 2014 | 27.3% | +62.5 |
| FY2013 | Mar 31, 2013 | -35.1% | +22.4 |
| FY2012 | Mar 31, 2012 | -57.5% | +24.0 |
| FY2011 | Mar 31, 2011 | -81.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -5.2% | +25.8 |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -10.4% | +10.2 |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -18.8% | +7.2 |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -9.5% | +7.5 |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -30.9% | +2.8 |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -20.7% | +10.4 |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -26.0% | +1.6 |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -17.0% | +37.3 |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -33.7% | +7.7 |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -31.0% | +12.4 |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -27.6% | +38.3 |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -54.3% | −23.8 |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -41.4% | −19.1 |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -43.4% | +84.7 |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -65.9% | −33.3 |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -30.5% | −27.9 |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -22.3% | +7.5 |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -128.1% | +41.6 |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -32.5% | −19.4 |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -2.7% | −4.8 |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -29.8% | −34.0 |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -169.7% | −129.4 |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -13.2% | +11.5 |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | 2.1% | +27.5 |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | 4.2% | −11.7 |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -40.3% | +33.3 |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -24.7% | +18.9 |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -25.4% | +31.6 |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | 15.9% | +95.1 |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -73.5% | +56.8 |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -43.5% | +22.3 |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -57.1% | +9.3 |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -79.1% | +12.3 |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -130.3% | −69.9 |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -65.8% | −548.6 |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -66.4% | +3.3 |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -91.5% | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | -60.5% | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | 482.8% | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | -69.7% | – |
See a number that looks wrong?